Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1

Abstract

The role of polymorph nuclear neutrophils (PMN) in limb ischemia and reperfusion has been recognized only in recent years. The present study aimed to investigate the systemic and local (in femoral venous blood) effects of intra-arterially or intravenously applied prostaglandin E₁ (PGE₁) on systemic and ischemia-induced local changes in neutrophil function. Thirty patients with intermittent claudication were randomly assigned to intra-arterial or intravenous infusion of prostaglandin E₁ (10 mgIAor15 mg IV over 30 min). Prior to infusion femoral arterial and venous blood samples were obtained from the predominantly affected leg under resting conditions and immediately after a 3-min period of ischemia induced by suprasystolic thigh compression. After 24 h additional blood samples were obtained at baseline, following infusion of prostaglandin E₁, and again after another 3-min period of ischemia following the prostaglandin E₁ infusion.

Intra-arterially administered prostaglandin E₁ caused an increase in the PMN count by 3.5 ± 2% (p,0.05) and a decrease in free oxygen radical production by 13 ± 8% (p,0.05) measured by whole blood chemiluminescence. Additionally, a trend for lower PMN filterabilities (9 ± 12%, NS) was observed. Intra-arterially infused prostaglandin E₁ significantly reduced the ischemia-induced decrease in neutrophil filterability (arterial and venous blood difference after ischemia - control: 22 ± 17% (p,0.05); IA PGE₁:8 ± 11% (NS), each compared to baseline). Intravenously administered prostaglandin E₁ showed similar systemic effects as the intra-arterial application, but did not affect the ischemia-induced changes in neutrophil filterability. In conclusion, prostaglandin E₁ reduces PMN activation in patients with peripheral arterial occlusive disease.

Keywords

neutrophil function peripheral arterial occlusive disease prostaglandin E1 reactive oxygen metabolites

References

Nash GB , Thomas PRS , Dormandy JA. Abnormal flow properties of white blood-cells in patients with severe ischaemia of the leg. Br Med J 1988; 296: 1699-1701.

Jackson MH , Collier A , Nicoll JJ et al. Neutrophil count and activation in vascular disease. Scot Med J 1992; 37: 41-43.

Neumann FJ , Waas W , Diehm C et al. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation 1990; 82: 1122-1129.

Engler RL , Dahlgren MD , Morris DD , Peterson MA , Schmid Schönbein GW. Role of leukocytes in the response to acute myocardial ischemia and reperfusion in the dog. Am J Physiol 1986; 251: H314-H322.

Goldstein IM , Roos A , Kaplan HB , Weissmann G. Complement and immunoglobulins stimulate superoxide anion production independent of phagocytosis. J Clin Invest 1975; 56: 1155-1157.

Gruber HE , Hoffer ME , McAllister DR et al. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation 1989; 80: 1400-1411.

Harlan JM. Leukocyte-endothelial interactions. Blood 1985; 65: 513-525.

Mehta JL , Nichols WW , Hehta P. Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J Am Coll Cardiol 1988; 11: 1306-1316.

Carden D , Smith JK , Korthuis RJ. Neutrophil-mediated microvascular dysfunction in postischemic skeletal muscle: role of granulocyte adherence. Circ Res 1990; 66: 1436-1444.

10.

Gumina RJ , Newmann PJ , Kenny D , Warltier DC , Gross GJ. The leukocyte cell adhesion cascade and its role in myocardial ischemia-reper-fusion injury. Basic Res Cardiol 1997; 92: 201-212.

11.

Ney P , Braun M , Szymanski Ch , Schrör K. Antiplatelet antineutrophil and vasodilating properties of 13, 14-dihydro PGE1 (PGE0) - an in vivo metabolite of PGE1 - in man. Eicosanoids 1991; 4: 177-184.

12.

Simmet T , Peskar BA. Prostaglandin E1 and arterial occlusive disease. Eur J Clin Invest 1988; 18: 549-552.

13.

Diehm C , Balzer K , Bisler H et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double blind trial. J Vasc Surg 1997; 25: 537-544.

14.

Carlson LA , Eriksson I. Femoral artery infusion of prostaglandin E1 in severe peripheral vascular disease. Lancet 1973; i: 155-156.

15.

Hecker G , König E , Ney P , Schrör K. Potent inhibition of PAF stimulated human platelets and polymorphonuclear leukocytes by the PGE1 analog OP-1206. In: Sinzinger H , Schrör K eds. Prostaglandins in clinical research. New York: Alan Liss Inc., 1987: 317-322.

16.

Schrör K , Hecker G. Different effects of E- and I-type prostaglandins on human platelet and polymorphonuclear cell function. In: Sinzinger H , Rogatti W eds. Prostaglandin E in atherosclerosis. Heidelberg: Springer, 1986: 22-26.

17.

Neumann FJ , Diehm C , Müller-Bühl U et al. Einfluß von Prostaglandin auf Funktion und Verformbarkeit neutrophiler Granulozyten bei Patienten mit peripherer arterieller Verschlußkrankheit im Stadium IV. Vasa 1989; 18 (suppl): 257-259.

18.

DeChalet LR , Shirley PS. Evaluation of chronic granulomatous disease by a chemiluminescence assay of microliter quantities of whole blood. Clin Chem 1981; 27: 1739-1741.

19.

Park BH , Fikrig SM , Smithwick EM. Infection and nitroblue tetrazolium reduction by neutrophils: a diagnostic aid. Lancet 1968; ii: 532-534.

20.

Nash GB , Jones JG , Mikita J , Dormandy JA. Methods and theory for analysis of flow of white cell subpopulations through micropore filters. Br J Haematol 1988; 70: 165-170.

21.

Mazzoni MC , Schmid-Schönbein GW. Mechanisms and consequences of cell activation in the microcirculation. Cardiovasc Res 1996; 32: 706-719.

22.

Zalokar JB , Richard JI , Claude JR. Leukocyte count, smoking and myocardial infarction. N Engl J Med 1981; 304: 465-468.

23.

Golup M , Zia P , Matsuno M , Horton R. Metabolism of prostaglandins A1 and E1 in man. J Clin Invest 1975; 56: 1404-1406.

24.

Peskar BA , Hesse WH , Rogatti W et al. Formation of 13, 14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease. Prostaglandins 1991; 41: 225-228.